EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unprecedented in vivo activity of telacebec against Mycobacterium leprae

Aurélie Chauffour, Emmanuelle Cambau, Kevin Pethe, Nicolas Veziris, Alexandra Aubry iD

PLOS Neglected Tropical Diseases · 2025

DOI: 10.1371/journal.pntd.0013076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2025. Verfasst von Aurélie Chauffour und 4 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, CNRS, INSERM, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Paris, France. Hauptthemen laut MEDLINE: Mycobacterium leprae, Leprostatic Agents, Leprosy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Association Française Raoul Follereau, Fondation Raoul Follereau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

New drugs targeting the electron transport chain (ETC) seem to be a promising advance in leprosy treatment. In this study, we evaluated the bactericidal activity of telacebec (TCB), a phase 2 drug candidate for tuberculosis, alongside known ETC-targeting antibiotics, bedaquiline (BDQ) and clofazimine (CFZ), as monotherapy or in combination. Methodology/ Principal Findings We used the reference leprosy proportional bactericidal mouse footpad model. Four hundred and ten mice were inoculated in the footpads with 5x10 4 to 5x10 0 bacilli of M. leprae strain THAI53 for the untreated control group and groups treated with drug-monotherapies, and with 5x10 4 to 5x10 1 for groups treated with drug-combinations. Mice were randomly allocated into the following groups: 2 control groups (untreated or standard multi drug therapy (MDT), rifampin, dapsone and clofazimine with dosing equipotent to human dosing) and 7 test groups (TCB 10mg/kg, bedaquiline 25mg/kg (BDQ), clofazimine 20mg/kg (CFZ), CFZ + BDQ, TCB + BDQ, TCB + CFZ, TCB + CFZ + BDQ). Mice in the test groups received either one month treatment (MDT) or a single dose of the drugs (TCB, RIF, BDQ, CFZ). Twelve months later, mice were sacrificed to enumerate M. leprae bacilli in the footpad. All the footpads became negative in the MDT, TCB and combination groups except in the TCB + CFZ group where 2 mice remained positive in the 5x10 4 inoculum.

Conclusion

We demonstrated that monotherapy of TCB exhibited bactericidal activity against M. leprae comparable to that of MDT and that all combination therapies were as effective as MDT, except the combination TCB + CFZ, possibly due to an antagonism between these two drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium lepraeLeprostatic AgentsLeprosyAnimalsMiceDisease Models, AnimalClofazimineDrug Therapy, CombinationMicrobial Sensitivity TestsElectron Transport Chain Complex ProteinsMice, NudeFemaleImidazolesPiperidinesPyridinesDiarylquinolines

Substanzen

telacebecLeprostatic AgentsbedaquilineClofazimineElectron Transport Chain Complex ProteinsImidazolesPiperidinesPyridinesDiarylquinolines

Autor:innen und Institutionen

  • Sorbonne Université, CNRS, INSERM, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Paris, France.
  • Université Paris Cité, IAME Inserm UMR 1137, Service de Mycobactériologie Spécialisée et de Référence, Laboratoire Associé du CNR des Mycobactéries et de La Résistance des Mycobactéries Aux Antituberculeux (CNR-MyRMA) A…
  • Lee Kong Chian School of Medicine, Nanyang Technological University, Experimental Medicine Building, Nanyang, Singapore.
  • Singapore Centre for Environmental Life Sciences Engineering (SCELSE), Nanyang Technological University, Nanyang, Singapore.
  • National Centre for Infectious Diseases (NCID), Nanyang, Singapore.
  • AP-HP, Sorbonne-Université, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France.

ORCID-Profile: Alexandra Aubry

Förderung

  • Association Française Raoul Follereau
  • Fondation Raoul Follereau

Zitieren

APA

Chauffour, A., Cambau, E., Pethe, K., Veziris, N., & Aubry, A. (2025). Unprecedented in vivo activity of telacebec against Mycobacterium leprae. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0013076

Vancouver

Chauffour A, Cambau E, Pethe K, Veziris N, Aubry A. Unprecedented in vivo activity of telacebec against Mycobacterium leprae. PLOS Neglected Tropical Diseases. 2025. doi:10.1371/journal.pntd.0013076

BibTeX
@article{Chauffour2025,
  author = {Chauffour, Aurélie and Cambau, Emmanuelle and Pethe, Kevin and Veziris, Nicolas and Aubry, Alexandra},
  title = {Unprecedented in vivo activity of telacebec against Mycobacterium leprae},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2025},
  doi = {10.1371/journal.pntd.0013076}
}
Kostenlos starten →